Indeed, patients carrying the allelic variants of FCGR2A, FCGR2C, and FCGR3A which exhibit increased affinity for human IgG demonstrated better responsiveness to anti-tumor antibody therapy in cases of B cell lymphomas, colorectal, renal, and breast cancers (20, 34–37). This evidence concerns the gene FCGR2A and B-cell non-Hodgkin lymphoma.